Qualitative Platelet Disorders: Causes, Tests, Treatment

·

Share

Qualitative platelet disorders are conditions in which platelets are present in normal or near-normal numbers but do not work properly, so the body struggles to form the first plug that stops bleeding. They can be inherited, such as Glanzmann thrombasthenia and Bernard-Soulier syndrome, or acquired, most often from medicines like aspirin, kidney failure, or bone marrow diseases. They typically cause easy bruising and mucosal bleeding, are diagnosed with platelet function tests, and are managed by treating the cause and using targeted measures such as desmopressin, tranexamic acid, or platelet transfusion when needed.

Platelet Function vs. Platelet Count

Platelet disorders fall into two broad groups. Quantitative disorders are problems with platelet count, which normally sits around 150 to 450 × 10⁹/L. Qualitative disorders are problems with platelet function, where the count may be entirely normal.

To stop bleeding, platelets must do three things in quick succession. They adhere to the damaged vessel wall, largely through von Willebrand factor binding a receptor called glycoprotein Ib. They release chemicals stored in their granules to recruit more platelets. Then they aggregate, sticking to one another through the glycoprotein IIb/IIIa receptor and fibrinogen. A defect at any of these steps produces a qualitative disorder. Our article on platelet aggregation mechanisms explains that final step in more detail.

Inherited Causes

Inherited qualitative platelet disorders are uncommon and are usually noticed in childhood, often after bleeding with tooth extraction, surgery, or the start of menstruation.

Disorder Defect Inheritance Distinctive features
Glanzmann thrombasthenia Missing or faulty GPIIb/IIIa, so platelets cannot aggregate Autosomal recessive Normal count and size; absent aggregation with most agonists but normal response to ristocetin
Bernard-Soulier syndrome Missing or faulty GPIb-IX-V, so platelets cannot adhere Usually autosomal recessive Giant platelets, mildly low count; absent response to ristocetin
Storage pool disease (dense granules) Too few dense granules to release their contents Varies Seen in Hermansky-Pudlak and Chédiak-Higashi syndromes, which also affect skin pigment
Gray platelet syndrome Absent alpha granules Usually autosomal recessive Large, pale-gray platelets on the smear; may lead to marrow scarring
Receptor and signaling defects Faulty responses to ADP, thromboxane, or other signals Varies Often mild; detected on aggregation testing

Acquired Causes

Acquired qualitative disorders are far more common and frequently overlooked. The main causes are:

  • Medicines: aspirin blocks the enzyme cyclooxygenase-1 permanently, so its effect lasts for the lifetime of the exposed platelets, around 7 to 10 days. Other NSAIDs have a shorter, reversible effect. Clopidogrel, prasugrel, and ticagrelor block the ADP receptor, and some antidepressants (SSRIs) also impair platelet function.
  • Kidney failure (uremia): waste products that build up in the blood interfere with platelet adhesion and aggregation.
  • Liver disease: often combines low platelet numbers, weaker platelet function, and low clotting factors.
  • Bone marrow disorders: myeloproliferative neoplasms and myelodysplastic syndromes can produce abnormal platelets, one of many hematologic conditions that do so.
  • Heart surgery on bypass: passage through the bypass circuit temporarily damages platelets.
  • Abnormal proteins: high levels of paraproteins, as in myeloma, can coat platelets and block them.

Signs and Symptoms

Platelet-type bleeding looks different from clotting-factor bleeding such as hemophilia. It tends to affect the skin and the lining of the nose, mouth, gut, and uterus rather than joints and muscles.

  • Easy bruising and pinpoint red spots called petechiae
  • Frequent or prolonged nosebleeds and bleeding gums
  • Heavy or prolonged menstrual periods
  • Excess bleeding after dental work, surgery, or childbirth
  • Bleeding from the stomach or bowel in more severe cases

Severity ranges widely. Many acquired and mild inherited defects cause trouble only after surgery or injury, while Glanzmann thrombasthenia and Bernard-Soulier syndrome can cause serious spontaneous bleeding.

How Qualitative Platelet Disorders Are Diagnosed

A structured approach, grounded in basic hematology, usually finds the answer.

  1. Detailed history: bleeding pattern, family history, and every medicine and supplement taken, including over-the-counter pain relievers.
  2. Blood count and smear: confirms the platelet count and shows size and appearance, such as giant or gray platelets.
  3. Clotting screen: the PT and APTT are usually normal in pure platelet disorders.
  4. Von Willebrand disease testing: it is the most common inherited bleeding disorder and causes very similar symptoms, so it must be excluded.
  5. Platelet function screening: an analyzer measures how quickly platelets plug a small opening under flow. The older bleeding time test is now rarely used.
  6. Light transmission aggregometry: the key test, measuring how platelets respond to ADP, collagen, epinephrine, arachidonic acid, and ristocetin. The pattern of responses points to the specific defect.
  7. Specialist tests: flow cytometry for missing surface glycoproteins, electron microscopy for granules, and genetic testing to confirm inherited disorders.

Aspirin and similar drugs should ideally be stopped for about 7 to 10 days before testing, if safe, because they distort the results.

Management and Treatment

Treat or Remove the Cause

For acquired disorders, stopping the responsible medicine or treating the underlying illness is often enough. In uremia, effective dialysis and correction of anemia improve platelet function.

Medicines That Reduce Bleeding

  • Desmopressin (DDAVP): boosts von Willebrand factor release and helps many mild inherited defects and uremic bleeding.
  • Tranexamic acid: stabilizes clots and is especially useful for nosebleeds, dental work, and heavy periods.
  • Hormonal treatments: can control heavy menstrual bleeding.

Transfusion and Specialist Therapy

Platelet transfusion is used for serious bleeding or surgery in severe disorders. In Glanzmann thrombasthenia, transfusions are used thoughtfully because patients can form antibodies against donor platelets; recombinant factor VIIa is an option when that happens. Stem cell transplantation is reserved for rare, very severe cases.

Everyday Prevention

Avoid aspirin and NSAIDs unless your hematologist approves, keep up good dental care, tell every doctor and dentist about your diagnosis before procedures, and consider carrying a medical alert card.

Frequently Asked Questions

Can you have a platelet disorder with a normal platelet count?

Yes. That is exactly what a qualitative platelet disorder is: the number is normal, but the platelets do not work properly. This is why a normal blood count does not rule out a bleeding problem.

Is taking aspirin a qualitative platelet disorder?

In effect, yes. Aspirin deliberately impairs platelet function to prevent heart attacks and strokes, and that same effect can increase bleeding. The effect wears off as new platelets are made over about a week to ten days.

How is Glanzmann thrombasthenia different from Bernard-Soulier syndrome?

Glanzmann thrombasthenia affects aggregation, with normal-sized platelets that cannot stick to one another. Bernard-Soulier syndrome affects adhesion, with giant platelets that cannot attach to the vessel wall. Aggregation testing with ristocetin helps tell them apart.

Are qualitative platelet disorders curable?

Acquired ones often resolve once the cause is removed. Inherited ones are lifelong but usually well controlled with preventive care and targeted treatment around bleeding episodes or procedures.

Written by
Haematology, Platelet Biology
Contact [email protected] severin_sonia Inserm U1048 I2MC September 24, 2020 A close relationship between adipocytes and megakaryocytes: a link with obesity Judith Cosemans holds a PhD degree (2009) in platelet biology, which focused on the dynamic regulation of thrombus stability. As a postdoc, she further developed flow chamber technology as a compatible alternative for experimental animal models of arterial thrombosis. As…
View Full Profile →
Web Admin Avatar